QuikReader

QuikReader

  • Latest
  • Top stories
  • Business
  • Tech
  • World
  • Politics
  • Sports
  • Lifestyle
  • Health
  • Science
  • Entertainment
  • More
    • Sources
Sign in

Latest in Cervomed’s

Sort by
1 items

  • CervoMed’s stock craters 77% after failed trial of treatment for rare brain disease

    CervoMed Inc.’s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with dementia with Lewy bodies, or DLB, failed to meet its main goals.
    MarketWatch - 1d
  • 1
  Follow topic
© 2024 QuikReader - About - Terms - Privacy